---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-013273"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:39:45.513113+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx reports positive Phase 2 data for AAV-GAD in Parkinson's; 18-point UPDRS improvement in high-dose group

## Summary
- AAV-GAD met primary safety endpoint; no SAEs related to treatment in 14-patient bridging study.
- High-dose group showed 18-point average improvement in UPDRS Part 3 off-medication (p=0.03); sham and low-dose showed no significant change.
- PDQ-39 quality-of-life score improved by 8 points (p=0.02) in high-dose and 6 points (p=0.04) in low-dose groups.
- 100% of high-dose participants reported PDQ-39 improvement vs 60% low-dose and 25% sham.
- Company plans to advance AAV-GAD into Phase 3 trial globally; total of 58 patients treated across program with no related SAEs.

## SEC filing metadata
- accession: 0001558370-24-013273
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000155837024013273/0001558370-24-013273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000155837024013273/mgtx-20241015x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-013273
- JSON: https://secwatch.observer/filing/0001558370-24-013273.json
- Plain text: https://secwatch.observer/filing/0001558370-24-013273.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.